N. Bulanova1, E. Ahsanova1, V. Popov1, T. Morozova1 (1Moscow RU)
Objective: to evaluate efficacy and safety of melatonin therapy in hypertensive patients based on the assessment of daily blood pressure monitoring.
Materials and Methods: 30 male patients with arterial hypertension aged from 27 to 58 yrs, mean age 45.5 ± 9.2 yrs, were included in the study. Daily ambulatory blood pressure monitoring (ABPM) with a portable BR-102 Plus blood pressure registrar (Schiller, Switzerland) was conducted on the first day of the study and on the next day after receiving a therapeutic dose of melatonin. Melatonin (Melaxen, Unipharm, Inc. (USA) was administered on the second day of the study, 3 mg once daily, 9:00-10:00 a.m. Average value of 24-hour, day-and night-time brachial systolic (SBP) and diastolic blood pressure (DBP) were assessed.
Results. Average 24-hour SBP and DBP values decreased after melatonin intake – from 124,6 ± 12,1 to 121,0 ± 10,2 mm Hg. (p <0.03), and 79,7 ± 8,8 to 77,3 ± 6,5 mm Hg. (p <0.03), respectively, as well as average day-time SBP and DBP values - from 128,2 ± 13,2 to 122,5 ± 9,9 mm Hg. (p <0.003) and 82,3 ± 9,7 to 78,5 ± 7,2 mm Hg. (p <0.006). Average night-time DBP and SBP values did not change (p> 0.05). There were no side effects observed after melatonin treatment.
Conclusions. A single administration of melatonin in a therapeutic dose causes a short-term reduction in blood pressure, predominantly due to the reduction of 24-hour and day-time systolic and diastolic blood pressure. Further studies are needed to prove the efficacy of melatonin in arterial hypertension treatment.